CDKN2A and breast cancer: In a pan-cancer analysis, amplification of KRAS and PIK3CA in the breast (66 and 114 of cases) and non-small cell lung cancer (46 and 48 of cases), TERT in non-small cell lung cancer (114 of cases) and ATR in breast cancer (36 of cases), were the most amplified genes, while deletion in CDKN2A in glioma (676 of cases), RB1 and TP53 in small cell lung cancer (15 of cases) were observed in these 14 different cancer types (Fig. 4C).